NICE is unable to make a recommendation on ciltacabtagene autoleucel (Carvykti) for treating relapsed or refractory multiple myeloma in adults. This is because Janssen withdrew its evidence submission for the appraisal. We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance